Jump to content

$15 drug gets COVID patients off oxygen support in under week – study

Infidel Dog

Recommended Posts

Fenofibrate could dramatically shorten the treatment time for severe COVID patients. 

Fourteen out of 15 severe COVID-19 patients who were treated in an investigator-initiated interventional open-label clinical study of the drug TriCor (fenofibrate) didn’t require oxygen support within a week of treatment and were released from the hospital, according to the results of a new Hebrew University of Jerusalem study.
Fenofibrate is an FDA-approved oral medication. The results were published on Researchsquare.com and are currently under peer review.
Specifically, the team that was led by HU’s Prof. Yaakov Nahmias carried out the study at Israel’s Barzilai Medical Center in coordination with the hospital’s head of the Infectious Disease Unit, Prof. Shlomo Maayan, and with support from Abbott Laboratories.
Link to comment
Share on other sites

  • Tell a friend

    Love Repolitics.com - Political Discussion Forums? Tell a friend!
  • Popular Now

  • Member Statistics

    • Total Members
    • Most Online

    Newest Member
  • Recent Achievements

  • Recently Browsing

    • No registered users viewing this page.
  • Create New...